Ublituximab：Briumvi - European Medicines Agency
Briumvi - European Medicines Agency
2023年7月13日—TheactivesubstanceinBriumvi,ublituximab,isamonoclonalantibody(atypeofprotein)thathasbeendesignedtorecogniseandattachtoa ...。其他文章還包含有：「AnewFDA」、「BRIUMVI®(ublituximab」、「Ublituximab」、「Ublituximab(TG-1101)」、「Ublituximab」、「UblituximabversusTeriflunomideinRelapsingMultiple...」、「Ublituximab」、「《多發性硬化症》TGTherapeutics的...」
查看更多 離開網站
A new FDA
https://pubmed.ncbi.nlm.nih.go
Ublituximab, an intravenous glycoengineered chimeric anti-CD20 IgG1 monoclonal antibody (mAb), is a new FDA-approved treatment for relapsing forms of Multiple ...
BRIUMVI ® (ublituximab
https://briumvi.com
BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and ...
Ublituximab
https://en.wikipedia.org
Ublituximab, sold under the brand name Briumvi, is an immunomodulator used for the treatment of multiple sclerosis. It is a CD20-directed cytolytic ...
Ublituximab (TG-1101)
https://pubmed.ncbi.nlm.nih.go
Ublituximab is a novel, glycoengineered anti-CD20 monoclonal antibody with single-agent activity in relapsed CLL. We report the results of a phase 2 study ...
Ublituximab
https://www.tgtherapeutics.com
Ublituximab is an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. When ublituximab binds to ...
Ublituximab versus Teriflunomide in Relapsing Multiple ...
https://www.nejm.org
Ublituximab is a type I chimeric IgG1 monoclonal antibody that binds to an epitope on CD20 that is distinct from the epitopes targeted by other ...
Ublituximab
https://pubmed.ncbi.nlm.nih.go
Ublituximab (ublituximab-xiiy; BRIUMVI™) is a glycoengineered anti-CD20 monoclonal antibody developed by TG Therapeutics, Inc. for the treatment of multiple ...
《多發性硬化症》TG Therapeutics的 ...
http://www.genetinfo.com
2. Ublituximab是一種研究性的醣基工程化單株抗體，作用在表現CD20的B細胞上的一個獨特表位(epitope)。在臨床試驗中，它可顯著降低復發風險、減少活動性或 ...